{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T08:21:36Z","timestamp":1787473296793,"version":"build-2736575974"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We report a case of a 61-year-old male patient with a complex hematologic history including pre-B acute lymphocytic leukemia, allogeneic stem cell transplant, and newly treated colon cancer followed by diagnosis of high-risk myelodysplastic syndrome (MDS), who exhibited abolishment of D antigen production. The patient\u2019s red blood cells (RBCs), which originally typed as group A, D+, again typed as group A, D+, after receiving stem cells from a female donor with the same blood type. The reactivity of the patient\u2019s RBCs was strong when tested with anti-D reagent until he was treated for colon cancer. Within 6 months of diagnosis of cancer, he developed a mixed-field D typing result followed by a complete D\u2013 phenotype over the course of a few weeks, coinciding with the new diagnosis of MDS and initiation of immunosuppressive therapy. Polymerase chain reaction (PCR) testing revealed no weak or partial D variants, and subsequent Sanger sequencing confirmed the presence of a conventional\n                    <jats:italic>RHD<\/jats:italic>\n                    gene. A more focused analysis by chromosomal microarray identified deletions involving the\n                    <jats:italic>RHD<\/jats:italic>\n                    locus, supporting the hypothesis that active MDS disrupted gene expression. The patient received another stem cell transplant, this time from a group AB, D+ male donor. In a short period of time, MDS re-emerged along with re-identification of microarray mutations encompassing\n                    <jats:italic>RHD<\/jats:italic>\n                    in female cells (from the first donor) even after the second stem cell transplant. However, D expression remained strong, underscoring the presence of enough male donor\n                    <jats:italic>RHD<\/jats:italic>\n                    expression to maintain the D+ phenotype.\n                  <\/jats:p>","DOI":"10.2478\/immunohematology-2025-012","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:57:18Z","timestamp":1761890238000},"page":"80-83","source":"Crossref","is-referenced-by-count":0,"title":["Loss of D expression associated with hematologic disease progression: a case report and review of the literature"],"prefix":"10.2478","volume":"41","author":[{"given":"Nalan","family":"Yurtsever","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine , Yale University School of Medicine , New Haven , CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Carmichael","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Yale University School of Medicine , New Haven , CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peining","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Genetics , Yale University School of Medicine , New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Di","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Genetics , Yale University School of Medicine , New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Genetics , Yale University School of Medicine , New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn","family":"Diadamo","sequence":"additional","affiliation":[{"name":"Department of Genetics , Yale University School of Medicine , New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Denomme","sequence":"additional","affiliation":[{"name":"Grifols Diagnostic Solutions , San Marcos, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tormey","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Yale University School of Medicine , New Haven , CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026082308011449549_j_immunohematology-2025-012_ref_001","doi-asserted-by":"crossref","unstructured":"Chenna D, Mohan G, Reddy VR, Shastry S. The disappearance of blood group antigens: a clue to the clinical diagnosis of leukemia. Transfus Apher Sci 2019;58:48\u20139. doi: 10.1016\/j. transci.2018.11.010.","DOI":"10.1016\/j.transci.2018.11.010"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_002","doi-asserted-by":"crossref","unstructured":"Sarma R, Kuli K, Kalita C, Iqbal A, Gupta S. Loss of blood group antigens in haematolymphoid malignancy: a case series from a cancer institute from north east India. APJCC 2024 2024;9:165\u20138. doi: 10.31557\/APJCC.2024.9.1.165.","DOI":"10.31557\/apjcc.2024.9.1.165-168"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_003","doi-asserted-by":"crossref","unstructured":"Bianco T, Farmer BJ, Sage RE, Dobrovic A. Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. Blood 2001;97:3633\u20139. doi: 10.1182\/blood.v97.11.3633.","DOI":"10.1182\/blood.V97.11.3633"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_004","doi-asserted-by":"crossref","unstructured":"Jeong IH, Seo JY, Choi S, Kim HY, Cho D. ABO blood group antigen changes in acute myeloid leukemia and no significant association with RUNX1 and GATA2 somatic variants. Ann Lab Med 2023;43:635\u20137. doi: 10.3343\/alm.2023.43.6.635.","DOI":"10.3343\/alm.2023.43.6.635"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_005","doi-asserted-by":"crossref","unstructured":"Yurtsever N, Lee ES, Pinatti L, Shah B, Tormey CA, Siddon AJ. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024;40:89\u201392. doi: 10.2478\/ immunohematology-2024-013.","DOI":"10.2478\/immunohematology-2024-013"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_006","doi-asserted-by":"crossref","unstructured":"Montemayor-Garcia C, Coward R, Albitar M, et al. Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocy themia. Transfusion 2017;57:2136\u20139. doi: 10.1111\/trf.14201.","DOI":"10.1111\/trf.14201"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_007","doi-asserted-by":"crossref","unstructured":"Salaru NN, Lay WH. Rh blood group mosaicism in a healthy elderly woman. Vox Sang 1985;48:362\u20135. doi: 10.1111\/j.1423-0410.1985.tb00197.x.","DOI":"10.1159\/000465790"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_008","doi-asserted-by":"crossref","unstructured":"Habibi B, Lopez M, Salmon C. Two new cases of Rh mosaicism. Selective study of red cell populations. Vox Sang 1974;27:232\u201342. doi: 10.1111\/j.1423-0410.1974.tb02413.x.","DOI":"10.1111\/j.1423-0410.1974.tb02413.x"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_009","doi-asserted-by":"crossref","unstructured":"Northoff H, Goldmann SF, Lattke H, Steinbach P. A patient, mosaic for Rh and Fy antigens lacking other signs of chimerism or chromosomal disorder. Vox Sang 1984;47:164\u20139. doi: 10.1111\/j.1423-0410.1984.tb01578.x.","DOI":"10.1159\/000466280"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_010","doi-asserted-by":"crossref","unstructured":"Callender ST, Kay HE, Lawler SD, Millard RE, Sanger R, Tippett PA. Two populations of Rh groups together with chromosomally abnormal cell lines in the bone marrow. Br Med J 1971;1:131\u20133. doi: 10.1136\/bmj.1.5741.131.","DOI":"10.1136\/bmj.1.5741.131"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_011","doi-asserted-by":"crossref","unstructured":"Bracey AW, McGinniss MH, Levine RM, Whang-Peng J. Rh mosaicism and aberrant MNSs antigen expression in a patient with chronic myelogenous leukemia. Am J Clin Pathol 1983;79:397\u2013401. doi: 10.1093\/ajcp\/79.3.397.","DOI":"10.1093\/ajcp\/79.3.397"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_012","doi-asserted-by":"crossref","unstructured":"Chow S, Pendergrast J, Ochoa-Garay G, et al. Mixed fields on RhD typing as an indication of loss of heterozygosity on chromosome 1p in acute myeloid leukemia. Leuk Lymphoma 2015;56:2196\u20139. doi: 10.3109\/10428194.2014.982641.","DOI":"10.3109\/10428194.2014.982641"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_013","doi-asserted-by":"crossref","unstructured":"Mertens G, Gielis M, Muylle L, de Raedt S. Loss of D and C expression in chronic myelomonocytic leukemia. Transfusion 1997;37:880\u20131. doi: 10.1046\/j.1537-2995.1997.37897424418.x.","DOI":"10.1046\/j.1537-2995.1997.37897424418.x"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_014","doi-asserted-by":"crossref","unstructured":"Sadough Shahmirzadi M, Lawicki S. A case of near total Rh(D) expression loss in a sickle cell patient following aplastic anemia and development of a transient auto-anti-D. Am J Clin Pathol 2022;158(Suppl):S113\u20134. doi: 10.1093\/ajcp\/aqac126.241.","DOI":"10.1093\/ajcp\/aqac126.241"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_015","doi-asserted-by":"crossref","unstructured":"Murdock A, Assip D, Hue-Roye K, et al. RHD deletion in a patient with chronic myeloid leukemia. Immunohematology 2008;24:160\u20134.","DOI":"10.21307\/immunohematology-2019-291"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_016","doi-asserted-by":"crossref","unstructured":"Kormoczi GF, Dauber EM, Haas OA, et al. Mosaicism due to myeloid lineage restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting. Blood 2007;110:2148\u201357. doi: 10.1182\/blood-2007-01-068106.","DOI":"10.1182\/blood-2007-01-068106"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_017","doi-asserted-by":"crossref","unstructured":"Cherif-Zahar B, Raynal V, Gane P, et al. Candidate gene acting as a suppressor of the RH locus in most cases of Rh-deficiency. Nat Genet 1996;12:168\u201373. doi: 10.1038\/ng0296-168.","DOI":"10.1038\/ng0296-168"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_018","doi-asserted-by":"crossref","unstructured":"Tilley L, Green C, Poole J, et al. A new blood group system, RHAG: three antigens resulting from amino acid substitutions in the Rh-associated glycoprotein. Vox Sang 2010;98:151\u20139. doi: 10.1111\/j.1423-0410.2009.01243.x.","DOI":"10.1111\/j.1423-0410.2009.01243.x"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_019","unstructured":"Cohn CS, Delaney M, Johnson ST, Katz LM, Schwartz J. The Rh system. In: Cohn CS, Ed. AABB technical manual. 21st ed. Bethesda, MD: AABB, 2023:358."},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_020","doi-asserted-by":"crossref","unstructured":"Reid ME, Westhoff CM. Rh, Kell, Duffy, and Kidd antigens and antibodies. In: Hillyer CD, Ed. Blood banking and transfusion medicine. 2nd ed. Philadelphia, PA: Elsevier, 2007:81\u20132.","DOI":"10.1016\/B978-0-443-06981-9.50012-0"},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_021","unstructured":"Lane WJ, Westhoff CM, Storry JR, Shaz BH. Human blood group antigens and antibodies. In: Hoffman R, Ed. Hematology: basic principles and practice. 7th ed. Philadelphia, PA: Elsevier, 2023:1785\u2013800."},{"key":"2026082308011449549_j_immunohematology-2025-012_ref_022","doi-asserted-by":"crossref","unstructured":"Mu S, Cui Y, Wang W, et al. A RHAG point mutation selectively disrupts Rh antigen expression. Transfus Med 2019;29:121\u20137. doi: 10.1111\/tme.12519.","DOI":"10.1111\/tme.12519"}],"container-title":["Immunohematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/immunohematology-2025-012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T08:01:46Z","timestamp":1787472106000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/immunohematology-2025-012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,9,1]]}},"alternative-id":["10.2478\/immunohematology-2025-012"],"URL":"https:\/\/doi.org\/10.2478\/immunohematology-2025-012","relation":{},"ISSN":["1930-3955"],"issn-type":[{"value":"1930-3955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}